A Brazilian invoice that may legalize medical marijuana and industrial hemp cultivation might quickly have its first debate on the ground of the decrease home of Congress, forward of its anticipated approval in that chamber earlier than the tip of this 12 months, federal deputy Paulo Teixeira advised Marijuana Enterprise Each day.
The invoice, PL 399/2015, would have far-reaching implications for Latin America’s largest medical hashish market, which at present depends on imported merchandise.
The present excessive worth of imported medical hashish has been one of many primary arguments in favor of the cultivation invoice: Proponents say home growers would be capable of provide the drugs at a decrease price.
In response to Teixeira, who leads a medical hashish particular fee within the decrease home, the invoice didn’t advance by the legislative course of in latest months primarily as a result of the nation’s municipal elections “paralyzed parliamentary work.”
“With these elections behind us, I anticipate the decrease home to shortly begin debating and approve the invoice earlier than the tip of the 12 months,” the consultant advised MJBizDaily.
The consultant mentioned the proposed regulation is “the results of an extended and profound debate that thought of one of the best of various hashish legislations in different nations.”
The invoice additionally requires Senate approval, which Teixeira mentioned might occur someday subsequent 12 months.
He doesn’t anticipate main adjustments within the invoice might be wanted to safe its remaining passage.
Requested by MJBizDaily about the potential for President Jair Bolsonaro opposing the reform, Teixeira mentioned it is going to be “tough” as a result of the invoice has broad help.
Subsequent week, nevertheless, the Nationwide Committee for Well being Expertise Incorporation (Conitec) will meet to judge the inclusion of 1 particular formulation of CBD within the Public Well being System (SUS).
A remaining determination, anticipated in early 2021, might make sufferers eligible to obtain public well being protection for that CBD formulation, successfully making it freed from cost.
That product, manufactured by Brazilian pharmaceutical agency Prati-Donaduzzi with imported uncooked materials, is the one one which has obtained “sanitary authorization” from the Nationwide Sanitary Surveillance Company (ANVISA).
It’s the solely product obtainable in pharmacies, however at a value of two,000 actual ($374) or extra, it stays unaffordable for a lot of sufferers, which has restricted the market.
If the CBD product would change into obtainable to sufferers freed from price, it might undermine hashish trade advocates who argue domestic-grown drugs is required to offer sufferers with inexpensive medical marijuana.
“By together with a CBD formulation into the SUS protection, the federal government, which is essentially in opposition to the invoice, might diminish one of many primary arguments for the proposed laws,” José Bacellar, CEO of Toronto-based VerdeMed, an organization targeted on the Brazilian market, advised MJBizDaily.
“We can’t anticipate taxpayers to should cowl the invoice of such an costly CBD product,” Teixeira mentioned.
Alfredo Pascual will be reached at [email protected]